Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins. Binds to neuregulin-1 (NRG1) and is activated by it; ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase (PubMed:20682778). May also be activated by CSPG5 (PubMed:15358134).
Involved in the regulation of myeloid cell differentiation (PubMed:27416908)
Monomer and homodimer. Heterodimer with each of the other ERBB receptors (Potential). Interacts with CSPG5 (PubMed:15358134).
Interacts with GRB7 (PubMed:9516479). Interacts with MUC1 (PubMed:12939402). Interacts with MYOC (By similarity).
Interacts with isoform 2 of PA2G4 (PubMed:11325528, PubMed:16832058). Found in a ternary complex with NRG1 and ITGAV:ITGB3 or ITGA6:ITGB4 (PubMed:20682778)
Epithelial tissues and brain
The cytoplasmic part of the receptor may interact with the SH2 or SH3 domains of many signal-transducing proteins
A form of lethal congenital contracture syndrome, an autosomal recessive disorder characterized by degeneration of anterior horn neurons, extreme skeletal muscle atrophy, and congenital non-progressive joint contractures (arthrogryposis). The contractures can involve the upper or lower limbs and/or the vertebral column, leading to various degrees of flexion or extension limitations evident at birth. LCCS2 patients manifest craniofacial/ocular findings, lack of hydrops, multiple pterygia, and fractures, as well as a normal duration of pregnancy and a unique feature of a markedly distended urinary bladder (neurogenic bladder defect).
The phenotype suggests a spinal cord neuropathic etiology.
An autosomal dominant myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood. Disease penetrance is incomplete.
An autosomal recessive disorder characterized by intestinal dysmotility due to aganglionosis (Hirschsprung disease), hypoganglionosis, and/or chronic intestinal pseudoobstruction. Additional variable features are progressive peripheral neuropathy, arthrogryposis, hypoplasia or aplasia of the olfactory bulb and of the external auditory canals, microtia or anotia, and facial dysmorphism. Some patients present structural cardiac anomalies and arthrogryposis with multiple pterygia.
| Cancer Type | Mutation Percentage |
|---|---|
| Central Nervous System Astrocytoma Grade Iv | 0.66% |
| Lung Adenocarcinoma | 1.75% |
| Lung Small Cell Carcinoma | 0.89% |
| Lung Squamous Cell Carcinoma | 1.77% |
| Oesophagus Adenocarcinoma | 2.79% |
| Oesophagus Squamous Cell Carcinoma | 0.47% |
| Pancreas Ductal Carcinoma | 0.81% |
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to ERBB3, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 31
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT00734305 | Advanced Solid Tumors | Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment | PHASE1 | COMPLETED |
| NCT02456701 | Thyroid Cancer | Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 | PHASE1 | COMPLETED |
| NCT03580382 | Melanoma | Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma | PHASE1, PHASE2 | TERMINATED |
| NCT05919537 | Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | PHASE1 | ACTIVE_NOT_RECRUITING |
| NCT01603979 | Solid Tumors | A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors | PHASE1 | COMPLETED |
| NCT02538627 | Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | PHASE1 | TERMINATED |
| NCT03065387 | Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation, ERBB2 Gene Amplification, ERBB2 Gene Mutation, ERBB3 Gene Mutation, ERBB4 Gene Mutation, KRAS Gene Mutation, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation | PHASE1 | ACTIVE_NOT_RECRUITING |
| NCT00730470 | Advanced Solid Tumors | Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors | PHASE1 | COMPLETED |
| NCT01451632 | Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Other Tumors With EGFR Dependence | A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | PHASE1 | COMPLETED |
| NCT05057013 | Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer, RAS Wild Type Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma (HCC), Melanoma, Non-small Cell Lung Cancer (NSCLC), Oesophageal Cancer, Ovarian Cancer, Pancreatic Cancer, Squamous Cell Cancer of the Head and Neck | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING |